Cord Blood America Makes Sales Pitch

The release, which provides a link to an interview with Matthew Schissler, the company's CEO, alludes to extremely high growth potential in the stem cell market segment.
Excerpt:
"In the interview, Mr. Schissler says investors should be increasingly interested in the stem cell sector because many more afflictions will be treated, and cured, by stem cells within the next two to five years. "We are the fastest growing stem cell company that we know about, and are highly undervalued," the CEO of Cord Blood America said. "We are positioning our Company to be in control of the inventory, which is crucial to significant corporate growth."
<< Home